Multibagger MNC Pharma stock sets record date to pay 400% final, debt-free dividend
AstraZeneca Pharma Ltd will pay a 400% dividend
Record date and ex-dividend date: The company’s board previously approved a 400% stock dividend earlier this year on May 26, 2022. The record date has been set for July 8, 2022 and the ex-dividend date is July 7. .
According to the company’s BSE filing, “Following our notification dated May 26, 2022, we wish to inform you that the record date to determine the shareholders’ right to payment of the final dividend for the financial year 2021-22 is May 8, 2022. July, 2022. The final dividend, if approved by shareholders, will be paid/sent to shareholders no later than September 6, 2022.”
AstraZeneca Pharma Ltd Share Outlook
The current market price of the share is Rs 2698 each with a 52 week high of Rs 3674.95 each and a 52 week low of Rs 2437 each. The stock’s PE is Rs 109, which is higher than the sector’s PE of 29.01. Compared to its peers, AstraZeneca has the highest PE TTM. The company has an ROE of 12.04%. It has an EPS of 24.64. It has a market capitalization of Rs 6712 crore.
Return: The stock gave a negative return of 25% in one year and a positive return of 193% in 5 years.
AstraZeneca Pharma Ltd Dividend History
AstraZeneca has declared a 500% stock dividend amounting to Rs 10 per share for the year ending March 2022. The dividend yield is 0.37 if the current market price of Rs 2698 is taken into account . The company has a good dividend track record and has declared no-fault dividends for the past 5 years. On May 26, 2022, it had declared a 400% stock dividend amounting to Rs 8 per share.
Introducing AstraZeneca Pharma Ltd
The company reported a 14% increase in QoQ revenue growth to Rs 235 crore, the highest in 3 years. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers the company’s manufacturing, sales and marketing activities in India. It is a listed company and a subsidiary of AstraZeneca Plc, UK. According to its website, it has more than 1,400 employees across the country who are committed to delivering life-changing medicines to patients through innovative science and global excellence in development and commercialization.